Background: Hidradenitis suppurativa is a skin disease of recurrent episodes of inflammatory nodules, abscesses, and scarring of the intertriginous regions, e.g. the axillae and groin. A dysregulated immune response to one or more unknown antigens in hidradenitis suppurativa has been suggested. One hypothetical element of this dysregulation may be the functionality of the cytokines. This study examines the serum level of anticytokine autoantibodies for interleukin (IL)-1α, IL-6, IL-10, IL-17A, IL-17E, IL-17F, and interferon-α. Method: Recombinant, carrier-free cytokines were coupled to microspheres. The coupled beads were incubated for 1 h in the dark with assay buffer-diluted sera, and subsequently for 30 min with polyclonal goat F(ab′)2 anti-human IgG phycoerythrin-conjugated antibody. Data are presented as the median fluorescence intensity of samples. Results: No difference in levels of anticytokine autoantibodies was demonstrated for any of the autoantibodies studied. Discussion: The data suggest that endogenously produced autoantibodies only play a minor role, if any, in hidradenitis suppurativa.

1.
Jemec GB: Clinical practice. Hidradenitis suppurativa. N Engl J Med 2012;366:158-164.
2.
Kelly G, Hughes R, McGarry T, van den Born M, Adamzik K, Fitzgerald R, Lawlor C, Tobin AM, Sweeney CM, Kirby B: Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol 2015;173:1431-1439.
3.
Meager A, Wadhwa M: Detection of anti-cytokine antibodies and their clinical relevance. Expert Rev Clin Immunol 2014;10:1029-1047.
4.
Barcenas-Morales G, Jandus P, Döffinger R: Anticytokine autoantibodies in infection and inflammation: an update. Curr Opin Allergy Clin Immunol 2016;16:523-529.
5.
Mizutani H, Ohmoto Y, Kupper TS, Shimizu M: Endogenous neutralizing anti-IL-1α autoantibodies in inflammatory skin diseases: possible natural inhibitor for over expressed epidermal IL-1. J Dermatol Sci 1998;20:63-71.
6.
Rosenau BJ, Schur PH: Autoantibodies to tumor necrosis factor in patients with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol 2009;36:753-756.
7.
Vincent T, Plawecki M, Goulabchand R, Guilpain P, Eliaou JF: Emerging clinical phenotypes associated with anti-cytokine autoantibodies. Autoimmun Rev 2015;14:528-535.
8.
Guldager DK, von Stemann JH, Larsen R, Bay JT, Galle PS, Svenson M, Ullum H, Hansen MB: A rapid, accurate and robust particle-based assay for the simultaneous screening of plasma samples for the presence of five different anti-cytokine autoantibodies. J Immunol Methods 2015;425:62-68.
9.
Kromann CB, Ibler KS, Kristiansen VB, Jemec GB: The influence of body weight on the prevalence and severity of hidradenitis suppurativa. Acta Derm Venereol 2014;94:553-557.
10.
Miller IM, Ring HC, Prens EP, Rytgaard H, Mogensen UB, Ellervik C, Jemec GB: Leukocyte profile in peripheral blood and neutrophil-lymphocyte ratio in hidradenitis suppurativa: a comparative cross-sectional study of 462 cases. Dermatology 2016;232:511-519.
11.
Riis PT, Søeby K, Saunte DM, Jemec GB: Patients with hidradenitis suppurativa carry a higher systemic inflammatory load than other dermatological patients. Arch Dermatol Res 2015;307:885-889.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.